The original process for manufacturing amorphous solid dispersions of Drug X involved spray drying crystalline Drug X and Eudragit L100, at a 3% solids loading. Initial batches exhibited a low product yield of 46% (%w/w) and required an extensive post drying step to remove the process solvent. The yield was determined to be a consequence of low solids loading, which resulted in the production of amorphous solid dispersions with sub-micron particles that were lost to the filter and presented clogging challenges. Solubility limitations prevented the solid loading to be increased beyond 3% and therefore it was hypothesized a more advantageous approach may be hot melt extrusion, if the physical and chemical properties of Drug X were suitable for extrusion.